We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Wrong incentives

27 June 2017 By Olaf Storbeck

Bain and Cinven’s 5.3 billion euro offer for the drugmaker collapsed despite a 49 percent premium. While the bidders may have a second go, the debacle is a lesson in how investment strategies that exploit misguided takeover rules can go terribly wrong.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)